A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia. (2022)

• Record Type: Journal Article
• Authors: Oshima, Yuri; Matsuura, Hiroyuki; Sakurai, Yusuke; Hirai, Kaho; Tani, Eriko; Yoshimoto, Naoki; Minami, Kenichi; Yamasaki, Fumio; Nishime, Mayu; Hirashima, Tomonori
• Is Part Of: Respiratory medicine case reports. Volume 36(2022)
• Publication Date: 2022
• Subjects: Cancer cachexia -- Anamorelin -- Lung cancer -- Multidisciplinary collaboration; ANA anamorelin -- BMI body mass index -- BW body weight -- BWL body weight loss -- CCX cancer cachexia -- CT computed tomography -- LBM lean body mass -- NSCLC non-small cell lung cancer -- PMI psoas muscle index; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2022.101609
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: Anamorelin (ANA) is approved for treating cancer cachexia (CCX) in Japan. We report the case of a 69-year-old man with stage IVB squamous cell lung cancer complicated by CCX, having a 13.6% weight loss in 6 months. After chemotherapy was initiated, his weight was further reduced. Therefore, we started ANA combined with a treatment approach by a multidisciplinary collaboration, including nutritionists and physical therapists. After initiation of ANA, the body weight, appetite, psoas muscle index, and physical functions rapidly improved during chemotherapy. ANA administration combined with a multidisciplinary collaboration approach can be an effective supportive therapy against CCX during chemotherapy.